Recombinant PCSK9 (Bococizumab Biosimilar) 抗体
This anti-PCSK9 (Bococizumab Biosimilar) antibody is a Mammalian Cells 单克隆 antibody detecting PCSK9 (Bococizumab Biosimilar) in ELISA. Suitable for 人.
Quick Overview for Recombinant PCSK9 (Bococizumab Biosimilar) 抗体 (ABIN7488036)
抗原
PCSK9 (Bococizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Mammalian Cells
克隆类型
单克隆
标记
This PCSK9 (Bococizumab Biosimilar) antibody is un-conjugated
应用范围
ELISA
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Bococizumab Biosimilar - Anti-PCSK9, NARC1, PC9 mAb
-
产品特性
- Antibody Type: IgG2-kappa
-
纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
-
亚型
- IgG2
-
-
-
-
限制
- 仅限研究用
-
-
-
缓冲液
- PBS pH 7.5
-
储存条件
- -80 °C
-
储存方法
- store at -80°C
-
-
- PCSK9 (Bococizumab Biosimilar)
-
物质类
- Biosimilar
-
背景
-
PF-04950615,RN-316
Bococizumab is a monoclonal antibody that was development by Pfizer targeting proprotein convertase subtilisin kexin type 9 (PCSK9). Bococizumab has been investigated for the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. -
CAS-编号
- 1407495-02-6
抗原
-
You are here:
